tipo
- journal article
A real-world evidence of immunotherapy adoption in non-small cell lung cancer (NSCLC) treatment and its transition from platinum-refractory to the first line of therapy.
Documento
- http://dx.doi.org/10.1200/JCO.2022.40.16_suppl.e18714
- http://dx.doi.org/10.1200/jco.2022.40.16_suppl.e18714
- http://https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.e18714][doi:10.1200/jco.2022.40.16_suppl.e18714
- http://https://ascopubs.org/doi/pdf/10.1200/JCO.2022.40.16_suppl.e18714][doi:10.1200/jco.2022.40.16_suppl.e18714
- https://doi.org/10.1200/JCO.2022.40.16_suppl.e18714][doi:10.1200/jco.2022.40.16_suppl.e18714
- Visão geral
- Pesquisas
- Identidade
- Informação adicional documento
- Outro
- Ver todos